TY - JOUR T1 - High-dose glucocorticoid treatment of near-fatal bocavirus lung infection results in rapid recovery JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00060-2021 VL - 7 IS - 2 SP - 00060-2021 AU - Matthias Obenaus AU - Oliver Schildgen AU - Dirk Schürmann AU - Ann-Christin von Brünneck AU - Martin Janz AU - Ulrich Keller AU - Bernhard Gebauer AU - Johannes Schilling AU - Stefan Schwartz AU - Benedikt Weissbrich AU - Thomas Schneider AU - Jörg Hofmann AU - Stephan Mathas Y1 - 2021/04/01 UR - http://openres.ersjournals.com/content/7/2/00060-2021.abstract N2 - Human bocavirus (HBoV), which belongs to Parvoviridae, is a well-defined pathogen of respiratory infections, particularly in young children [1]. In contrast, the frequency of HBoV infections in adults with respiratory symptoms is virtually unknown and its causative role in respiratory failure is debated [1, 2]. Furthermore, the observation that dexamethasone is beneficial in COVID-19 patients with respiratory failure requiring respiratory support has gained great interest [3]. However, whether glucocorticoid treatment is useful in other severe viral respiratory diseases is a matter of controversy [4].Human bocavirus (HBoV) has to be considered a life-threatening pathogen in adults with atypical pneumonia. Pulsed high-dose glucocorticoid treatment may be beneficial in patients suffering from severe pulmonary disease caused by HBoV or other viruses. https://bit.ly/3epiMyO ER -